title: Liver transplantation for type I and type IV glycogen storage disease.
abstract: Progressive liver failure or hepatic complications of the primary disease led to orthotopic liver transplantation in eight children with glycogen storage disease over a 9-year period. One patient had glycogen storage disease (GSD) type I (von Gierke disease) and seven patients had type IV GSD (Andersen disease). As previously reported [19], a 16.5-year-old-girl with GSD type I was successfully treated in 1982 by orthotopic liver transplantation under cyclosporine and steroid immunosuppression. The metabolic consequences of the disease have been eliminated, the renal function and size have remained normal, and the patient has lived a normal young adult life. A late portal venous thrombosis was treated successfully with a distal splenorenal shunt. Orthotopic liver transplantation was performed in seven children with type N GSD who had progressive hepatic failure. Two patients died early from technical complications. The other five have no evidence of recurrent hepatic amylopectinosis after 1.1-5.8 postoperative years. They have had good physical and intellectual maturation. Amylopectin was found in many extrahepatic tissues prior to surgery, but cardiopathy and skeletal myopathy have not developed after transplantation. Postoperative heart biopsies from patients showed either minimal amylopectin deposits as long as 4.5 years following transplantation or a dramatic reduction in sequential biopsies from one patient who initially had dense myocardial deposits. Serious hepatic derangement is seen most commonly in types I and IV GSD. Liver transplantation cures the hepatic manifestations of both types. The extrahepatic deposition of abnormal glycogen appears not to be problematic in type I disease, and while potentially more threatening in type IV disease, may actually exhibit signs of regression after hepatic allografting.
authors.affiliation: Department of Surgery, Children's Hospital, University of Pittsburgh, Pennsylvania 15213.
authors.forename: R
authors.initials: R
authors.lastname: Selby
authors.forename: T E
authors.initials: TE
authors.lastname: Starzl
authors.forename: E
authors.initials: E
authors.lastname: Yunis
authors.forename: S
authors.initials: S
authors.lastname: Todo
authors.forename: A G
authors.initials: AG
authors.lastname: Tzakis
authors.forename: B I
authors.initials: BI
authors.lastname: Brown
authors.forename: R S
authors.initials: RS
authors.lastname: Kendall
mesh_terms: D000687:Amylopectin / Q000032:analysis; D001706:Biopsy; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D005953:Glycogen Storage Disease Type I / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D006011:Glycogen Storage Disease Type IV / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008099:Liver / Q000473:pathology; D016031:Liver Transplantation; D008297:Male; D009132:Muscles / Q000737:chemistry / Q000473:pathology; D009206:Myocardium / Q000737:chemistry / Q000473:pathology; D011597:Psychomotor Performance; D015996:Survival Rate
chemical_list: D000687:Amylopectin